Insights provides context and perspective about key pharmacy trends and issues

Female lab scientist filling a vial with a liquid sample
Specialty
Gene Therapies: Promising, Costly, Complex
Gene therapies bring hope for patients with conditions with few or no treatments, but also other considerations including safety and cost. More
Feature
Icon depicting a virus cell
Specialty
Future of HIV Treatments
HIV drugs are a $17 billion market and the pipeline has seen dramatic shifts in recent years. Ongoing monitoring, effective utilization management, and a focus on adherence can help control... More
Briefing
Senior canoeist outdoors
Specialty
Potential Market Expansion for Prostate Cancer Drug
Blockbuster cancer drug Zytiga may become first-line treatment for patients with metastatic, castration-resistant cancer, greatly expanding its market and cost impact. More
Feature
Icon of smart watch and drug vial
Specialty
Pharmacy of the Future
Wearable health trackers, secure texting, and new biomarker technology allow for increased patient engagement and better health outcomes. More
Briefing
Icon of an infusion bag, overlaying a rising line graph
Specialty
Managing the MS Cost Challenge
Multiple Sclerosis is a $19 billion market worldwide, and the third most expensive specialty drug spend category. Recently approved Ocrevus is likely to add to cost of treatment and needs... More
Briefing
Icon of a syringe and dollar sign
Specialty
Costly and Complex
The specialty pipeline has many promising new drugs. The complexity and personalized nature of some medications require that they be managed under the medical benefit. More
Briefing
Icon of syringe, infusion bag and dollar sign tag
Specialty
New Treatments, Added Costs
The specialty pharmaceutical market continues to grow as a percentage of the overall prescription drug market, and its impact on payor trend also is rising. More
Feature
Icon of infusion bag and dollar bills
Specialty
Managing Specialty Drug Spend Under the Medical Benefit
Specialty spend under medical benefit is growing and a comprehensive medical benefit management strategy can help ensure appropriate utilization and control costs More
Feature
Icon of syringe and pills
Specialty
A Robust and Evolving Specialty Pipeline
After a 19-year high for new drug approvals in 2015, 2016 saw a sharp decline. Including the six new biologics approved by the Center for Biologics Evaluation and Research (CBER), 2015 saw... More
Feature
Pills and female pharmacist icon
Specialty
The Evolution of Specialty Management
The impact of specialty medications on payors’ trend is not only rising, it is doing so more rapidly than ever before. From 2010 to 2015, spending on specialty drugs doubled, accounting for... More
Feature